# AMA Says Marijuana Has Benefits And Risks For Older Adults, While Supporting A Ban On … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ama-says-marijuana-has-benefits-and-risks-for-older-adults-while-supporting-a-ban-on/ > **Published:** 2026-07-07T12:19:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:43-04:00 > **Clinical Summary:** AMA supports cannabis agitation management in older adults. Clinical evidence on benefits, risks, and safe prescribing for geriatric patients. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. AgingResearchPolicyPainAnxietySafetyMental Health Why This Matters Clinicians treating older adults now have authoritative guidance from the AMA to consider cannabis as a potential therapeutic option for specific conditions like agitation while remaining alert to safety risks in this vulnerable population. This position validates clinical exploration of [cannabis benefits](https://cedclinic.com/cannabis-and-sexuality-benefits-intimacy/) while establishing the need for rigorous evidence-gathering, enabling practitioners to have informed conversations with elderly patients about risks and potential benefits rather than defaulting to categorical dismissal. The AMA’s stance shifts the clinical landscape toward individualized assessment of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in older adults, where age-related pharmacokinetic changes and polypharmacy interactions make evidence-based dosing and monitoring protocols increasingly important. Clinical Summary The American Medical Association has issued a formal position recognizing that cannabis may offer [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) for older adults, particularly in managing agitation and other conditions, while simultaneously acknowledging documented risks in this vulnerable population. This stance represents a significant shift in organized medicine’s approach to cannabis, moving from blanket opposition toward evidence-based consideration of potential clinical applications. However, the AMA continues to oppose federal legalization for non-medical purposes, reflecting concern about uncontrolled access and [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) implications. For clinicians caring for older patients, this position provides some clinical and professional support for carefully considering cannabis as a therapeutic option when appropriate, though it underscores the need for rigorous research to establish safe dosing, drug interactions, and efficacy in aging populations who are often taking multiple medications. The practical takeaway is that while cannabis warrants consideration as a potential therapeutic agent in select older adult patients, clinicians should maintain cautious individualized assessment, stay current with emerging evidence, and prioritize research-based protocols over presumed benefits until more robust clinical data becomes available. Dr. Caplan’s Take “What the AMA statement reflects is where we actually stand clinically: there are legitimate therapeutic signals in cannabis for certain geriatric conditions like agitation and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), but we lack the rigorous, large-scale human trials in older populations that would let us prescribe with real confidence, and the drug interaction profile in polypharmacy is genuinely complex. Until we have better evidence and clearer dosing guidance, my approach is cautious engagement with individual patients, not blanket enthusiasm or dismissal.” Clinical Perspective 💊 The American Medical Association’s nuanced stance on cannabis in older adults reflects growing recognition that cannabinoids may offer symptom relief for conditions like agitation, [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), and chemotherapy-related nausea, yet clinical application remains challenging due to limited rigorous evidence, heterogeneous cannabis products, and age-related pharmacokinetic changes that increase older adults’ vulnerability to cognitive and fall-related adverse effects. Clinicians should note that enthusiasm for cannabis in this population is tempered by the lack of standardized dosing guidelines, the confounding effects of polypharmacy (particularly with medications metabolized through cytochrome P450 pathways), and variability in state-level legal and regulatory frameworks that may restrict access or clinical guidance. While supporting expanded research is prudent, the current evidence base does not yet support cannabis as a first-line therapy for most geriatric conditions, and providers caring for older adults should continue to prioritize conventional 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20AMA%20Says%20Marijuana%20Has%20Benefits%20And%20Risks%20For%20Older%20Adults%2C%20While%20Supporting%20A%20Ban%20On%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68523)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68523)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20AMA%20Says%20Marijuana%20Has%20Benefits%20And%20Risks%20For%20Older%20Adults%2C%20While%20Supporting%20A%20Ban%20On%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68523)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Inhaled cannabis replaces opioids for back pain study](https://cedclinic.com/inhaled-cannabis-replaces-opioids-for-back-pain-study/) - [Georgia Expands Medical Cannabis Access: New Pharmacy and Product Rules Explained](https://cedclinic.com/georgia-medical-cannabis-pharmacy-distribution-2026/) - [Pain Cannabinoids THC CBD Components Matter](https://cedclinic.com/pain-cannabinoids-thc-cbd-components-matter/) 📰 Source: [https://www.marijuanamoment.net/ama-says-marijuana-has-benefits-and-risks-for-older-adults-while-supporting-a-ban-on-flavored-cannabis-vapes/](https://www.marijuanamoment.net/ama-says-marijuana-has-benefits-and-risks-for-older-adults-while-supporting-a-ban-on-flavored-cannabis-vapes/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).